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Abstract
Background & Aims—Non-alcoholic fatty liver disease (NAFLD) was shown to 
disproportionally affect Hispanic persons. We examined the prevalence of suspected NAFLD in 
Hispanic/Latino persons with diverse backgrounds.
Methods—We studied the prevalence of suspected NAFLD among 12,133 persons included in 
The Hispanic Community Health Study/Study of Latinos. We collected data on levels of 
aminotransferase, metabolic syndrome (defined by National Cholesterol Education Program-Adult 
Treatment Panel III guidelines), demographics, and health behaviors. Suspected NAFLD was 
defined based on increased level of aminotransferase in the absence of serologic evidence for 
common causes of liver disease or excessive alcohol consumption. In multivariate analyses, data 
were adjusted for metabolic syndrome, age, acculturation, diet, physical activity, sleep, and levels 
of education and income.
Results—In multivariate analysis, compared to persons of Mexican heritage, persons of Cuban 
(odds ratio [OR], 0.69; 95% confidence interval [CI], 0.57–0.85), Puerto Rican (OR, 0.67; 95% 
CI, 0.52–0.87), and Dominican backgrounds (OR, 0.71; 95% CI, 0.54–0.93) had lower rates of 
suspected NAFLD. Persons of Central American and South American heritage had a similar 
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prevalence of suspected NAFLD compared to persons of Mexican heritage. NAFLD was less 
common in women than men (OR, 0.49; 95% CI, 0.40–0.60). Suspected NAFLD associated with 
the metabolic syndrome and all 5 of its components.
Conclusion—Based on an analysis of a large database of health in Latino populations, we found 
the prevalence of suspected NAFLD among Hispanic/Latino individuals to vary by region of 
heritage.
Keywords
HCHS/SOL; steatohepatitis; obesity; Hispanic Americans; life style
Background and Aims
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the 
United States with a prevalence estimate of 30% 1. NAFLD is an umbrella term including 
both bland steatosis and non-alcoholic steatohepatitis (NASH), with the latter being a 
pathologic entity consisting of hepatic steatosis and inflammation. Persons with NASH are 
at risk for progression to cirrhosis 2 hepatocellular carcinoma, and liver disease-related 
mortality 3. The prevalence of NASH in the US population is estimated to be between 3% to 
5% 1. A number of studies have found that Hispanic/Latino individuals, have the highest 
rate of NAFLD 4–7. NASH may be seen in up to 9.9%–19.4% of Hispanic persons within 
the United States 6, 7. Public health issues related to obesity such as NAFLD/NASH merit 
further study in the Hispanic/Latinos population. Hispanic/Latinos represent the largest 
minority population under the age of 18 in the United States 8, and nearly half of Hispanic 
youths between the ages of 6–11 years are overweight or obese 9.
NAFLD is a complex disease state resulting from an interplay between genetic, behavioral, 
and environmental factors. Ethnic differences in NAFLD are likely related to multiple 
causes 7, 10. For example, Hispanic/Latino persons have the highest rates of abdominal 
obesity in the US and were found to have a greater prevalence of the patatin-like 
phospholipase domain-containing protein 3 (PNPLA3) genetic polymorphism, which are 
both associated with NAFLD 11, 12. Population based differences in insulin resistance and 
obesity appear important as the histologic features of NAFLD are comparable between 
Hispanics and non-Hispanics when controlling for these risk factors13, 14. An important 
shortcoming of studies of NAFLD in Hispanics/Latinos in the US is that they primarily have 
focused on persons of Mexican American origin 5, 6. Hispanics/Latinos represent a diverse 
group of individuals who share a common language, but have differences in ancestry and 
culture. Chronic medical conditions do not necessarily affect all groups of Hispanic/Latinos 
with the same frequency. For instance, the prevalence and severity of pediatric asthma was 
found to disproportionally affect Puerto Rican youths 15. Studying Latinos of different 
heritage provides a means to assess rates of NAFLD in this heterogeneous group and to 
identify cultural and behavioral correlates of NAFLD in Hispanics/Latinos in the US.
The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was designed to 
estimate risk factors and the prevalence of chronic diseases among several distinct Hispanic/
Latino groups in the US. Using elevated aminotransferase levels in the absence of other 
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common causes of liver disease, this report describes the prevalence of suspected NAFLD 
by Hispanic/Latino group, as well as age group, which is consistent with a prior analysis of 
the National Health and Nutrition Examination Survey (NHANES) 6. In addition, the report 
describes behavioral and environmental factors associated with suspected NAFLD among 
diverse Hispanic/Latino groups.
Methods
The design and implementation of HCHS/SOL cohort has been described in detail 16. 
Briefly, HCHS/SOL is a multi-center study of 16,415 Hispanic/Latino adults that includes 
persons of Mexican, Puerto Rican, Dominican, Cuban, Central American, and South 
American backgrounds recruited from four US communities (Chicago, Bronx, Miami, and 
San Diego) from 2008 to 2011. Households in selected census tracts in the study regions 
were selected by stratified random sampling. Household members were contacted by 
telephone and home visits. Persons ages 18–74 years who self-identified as being Hispanic/
Latino, had no plans to move over a 6 month period, and were able to attend a clinic 
examination were eligible to participate. Forty-two percent of eligible individuals enrolled in 
the study. The study was approved by the Institutional Review Board at each participating 
institution. All participants provided written informed consent.
Participants completed interviews to evaluate demographic data and health behaviors. 
Physical exams included abdominal girth with patients wearing light clothing, and resting 
brachial blood pressure was measured three times in a seated position. All blood samples 
were collected after an eight hour at the beginning of the study visit. Blood samples were 
handled uniformly and were centrifuged and frozen within 45 minutes of collection. Two 
food propensity questionnaires using National Cancer Institute method were used to estimate 
total daily carbohydrate consumption. Total carbohydrate intake was chosen as a dietary 
measure given associations between carbohydrate intake and inflammatory activity in 
persons with NAFLD 17, 18. Self-reported physical activity was quantified by combining the 
intensity of physical activity in metabolic equivalents and the duration of physical activity 
during work, transport and recreational activity. Alcohol use was determined by a 
questionnaire asking participants to detail the number of standard drinks of wine, beer and 
hard liquor consumed per week.
In the current analysis, demographic data consisted of age, gender and Hispanic/Latino 
background of origin. Education was categorized as <13 years, 13–15 years and >15 years. 
Health care use was measured as the number of physician visits during the prior 12 months. 
Acculturation was evaluated by Short Acculturation Scale for Hispanics language subscale. 
The Short Acculturation Scale for Hispanics language subscale characterizes language use 
on a 5-point ordinal number scale with a value of 1 for Spanish language only, 2 for Spanish 
better than English, 3 for both equal, 4 for English better than Spanish and 5 for English 
only. Household income was divided into <$10,000, $10,000–20,000, $20,001–40,000, 
$40,001–75,000, and > $75,000 per year.
The metabolic syndrome was defined as abnormal levels of three or more of the following 
metabolic components in accordance with National Cholesterol Education Program- Adult 
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Treatment Panel III (NCEP-ATP III) criteria: increased waist circumference (>102 cm in 
men; > 88 cm in women), elevated triglycerides (>150 mg/dl), decreased high density 
lipoprotein (HDL) [< 40 mg/dl in men; < 50 mg/dl in women), elevated blood pressure 
(>130/85) and increased fasting glucose (> 110 mg/dl) 19. Diabetes was defined as the use of 
medication to treat diabetes or the presence of a fasting blood sugar ≥ 126 mg/dl, non-
fasting blood sugar ≥ 200 mg/dl, post oral glucose tolerance test blood sugar ≥ 200 mg/dl or 
glycosylated hemoglobin ≥ 6.5%. Physical activity was compared by quartiles. Sleep habits 
were evaluated by a questionnaire assessing the quality of sleep over the prior four weeks.
The aminotransferase thresholds for the designation of suspected NAFLD and exclusion 
criteria used in this study were based on a previous analysis from the NHANES III survey 
by Clark et al 6. Elevated aminotransferase levels suggestive of NAFLD were defined as 
either aspartate aminotransferase (AST) >37 IU/mL or alanine aminotransferase (ALT) >40 
IU/mL for men and AST or ALT >31 IU/mL for women. Although it is recognized that 
aminotransferases have limitations in the identification of NAFLD, patterns of ethnic 
differences in prevalence of NAFLD observed in population based data using 
aminotransferases6 were confirmed with imaging5 and histologic findings7. Exclusion 
criteria included missing aminotransferase data, seropositivity for hepatitis C or hepatitis B 
surface antigen, alcohol consumption > 7 drinks per week in women or > 14 drinks per week 
in men, and a transferrin saturation greater than 50%.
A total of 4,282 participants were excluded due to seropositivity for hepatitis B or C 
(n=356), excess alcohol consumption (n=799), elevated transferrin saturation (n=592), 
missing AST or ALT (n=174), missing data of interest (n=2,000), or the participant did not 
identify as being a member of one of the six Hispanic/Latino background groups or age >74 
(n=361). The most common missing data of interest was income (n=1339), healthcare use 
(n=217), physical activity (n=117) and dietary carbohydrate (n=111). As such, 12,133 
persons comprised the study cohort including 5,208 persons of Mexican heritage, 1,701 
persons of Cuban heritage, 1,916 persons of Puerto Rican heritage, 1,083 persons of 
Dominican heritage, 1,342 persons of Central American heritage and 883 persons of South 
American heritage.
Statistical Analysis
Reported values (means, prevalence, and odds ratios [ORs]) were weighted to adjust for 
sampling probability and nonresponse 16, 20, 21. Descriptive characteristics were computed 
for all participants by sex and Hispanic/Latino background and were age standardized to the 
2010 United States population as was previously described 21. Prevalence of elevated 
aminotransferase levels were calculated by sex and Hispanic/Latino background. The 
prevalence of suspected NAFLD was stratified by age group, sex, and Hispanic/Latino 
background. Survey-specific procedures were used to compute 95% confidence intervals to 
account for the 2-stage sampling design, stratification, and clustering. Comparisons across 
Hispanic/Latino groups were performed using the overall Wald test.
Logistic regression analyses were used to examine association of demographic, metabolic, 
and behavioral factors in the SOL cohort and prevalence of suspected NAFLD for men and 
women separately. All variables were entered into the multivariate analysis. Multivariate 
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analysis was performed with each component of metabolic syndrome analyzed individually. 
Odds ratio with 95% CIs were computed. All statistical tests were 2-sided at a significance 
level of 0.05 and performed using SAS version 9.2 (SAS Institute).
Results
The mean age of the study population was 41.7 (41.1, 42.2) years. A majority of subjects 
were female (54.3%). Baseline characteristics for the study population are presented in 
Table 1, stratified by background with participants of Mexican background serving as the 
reference group. Persons of Mexican background were younger than those from each of the 
other ethnic groups. Higher rates of the metabolic syndrome were seen in persons of Puerto 
Rican background, and lower rates of the metabolic syndrome were observed in persons 
with Dominican and South American background. Additional differences were seen in 
acculturation, health care use, sleep disturbance, carbohydrate consumption and physical 
activity.
The prevalence of suspected NAFLD by Hispanic/Latino group and gender is shown in 
Figure 1. Suspected NAFLD was identified in 19.1% of participants overall, and was more 
common in men (23.2%) compared to women (15.7%, p=<0.001). Considering men and 
women together, Mexican and Central Americans had the highest prevalence of suspected 
NAFLD. Data from men showed significantly lower rates of rates of suspected NAFLD in 
persons of Puerto Rican background. Among women, lower rates of NAFLD were observed 
in the Cuban, Dominican, and South American groups
The relation between suspected NAFLD and metabolic, socio-demographic, and behavioral 
factors is presented in Table 2. The metabolic syndrome, elevated waist circumference, 
elevated triglycerides and decreased HDL cholesterol were strongly associated with 
suspected NAFLD in both men and women. Higher carbohydrate intake was associated with 
suspected NAFLD in the total cohort. Other associations varied by gender. Specifically, 
elevated blood pressure was associated with suspected NAFLD in men, while impaired 
fasting glucose was correlated with suspected NAFLD in women. Moreover, there was an 
inverse relation between educational level and suspected NAFLD in women. Acculturation, 
healthcare use, sleep, physical activity and income were not associated with suspected 
NAFLD in either gender.
A multivariable model was constructed to further assess risk factors for suspected NAFLD 
(Table 3). When controlling for all measured variables, Mexican Americans continued to 
have significantly higher rates of suspected NAFLD than persons of Cuban, Puerto Rican 
and Dominican background. The metabolic syndrome components including waist 
circumference, dyslipidemia, and elevated fasting glucose remained significantly associated 
with suspected NAFLD. Age greater than 40 also was associated with lower rates of 
suspected NAFLD. A secondary multivariate analysis was conducted replacing impaired 
fasting glucose and waist circumference with the prevalence of diabetes and body mass 
index, respectively. In that analysis, persons of Cuban (OR 0.72, 95% CI 0.59,0.88), Puerto 
Rican (OR 0.62, 95% CI 0.48,0.80) and Dominican (OR 0.64, 95% CI 0.49,0.85) heritage 
continued to have the lower rates of suspected NAFLD compared to those of Mexican 
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heritage. Additional gender specific data is shown in Table 3. Notable, both men and women 
of Puerto Rican background had lower rates of suspected NAFLD. Gender specific 
differences were noted in persons of Cuban and Dominican background. Specifically, in 
persons of Cuban and Dominican heritage, lower rates of suspected NAFLD were driven by 
women. In men, suspected NAFLD decreased with increasing age, a finding not observed in 
women. Components of the metabolic syndrome were associated with NAFLD in both 
genders with a few exceptions shown in Table 3.
Conclusions
The growing number of Hispanic/Latinos in the US 8, the high rates of childhood obesity 
among Hispanic youths 9, and the high prevalence of NAFLD 5 makes understanding the 
epidemiology of NAFLD in Hispanic/Latinos particularly important. The current study of 
more than 12,000 people from the unique HCHS/SOL cohort provides essential new 
information regarding the prevalence of NAFLD among diverse Hispanic/Latino groups. 
Persons of Mexican and Central American backgrounds had a higher prevalence of NAFLD 
compared to those of Puerto Rican, Dominican, and Cuban heritage. Persons with South 
American heritage had lower rates of suspected NAFLD compared to persons of Mexican 
heritage, however, the effect was not maintained when adjusting for other variables. These 
differences were not explained by differences in rates of metabolic syndrome, diet, physical 
activity, or acculturation. That is, when controlling for these factors, suspected NAFLD was 
still less common in Hispanic/Latino persons of Puerto Rican, Dominican and especially 
Cuban backgrounds. Suspected NAFLD was more common in individuals younger than age 
40, and in men.
With prior studies highlighting the association of body mass index and diabetes13, 14 with 
the prevalence of NAFLD, a separate multivariate analysis was conducted substituting body 
mass index and diabetes for waist circumference and impaired fasting glucose, respectively. 
The differences seen in the prevalence of NAFLD based on heritage were unchanged. Total 
dietary carbohydrate was associated with suspected NAFLD in univariate ananlysis but not 
multivariate analysis. Moreover, in further analysis, total caloric intake was not associated 
with suspected NAFLD in multivariate analysis. Other factors including acculturation, 
health care use, physical activity, education and income were not directly associated with the 
odds of having NAFLD.
Although previous studies have highlighted the increased prevalence of NAFLD in 
Hispanic/Latino persons 4, 5, 7, none of these studies have examined rates of NAFLD based 
on background. The US Hispanic/Latino population is comprised of persons of diverse 
heritage. The persistence of differences in rates of suspected NAFLD when controlling for 
factors typically associated with NAFLD such as physical activity and the metabolic 
syndrome suggests a role for other undefined factors. Evidence is mounting that genetic 
polymorphisms can contribute to the development of NAFLD 22 such as the risk allele for 
PNPLA3 11. Although the function of the PNPLA3 gene is not known, the risk allele is 
associated with higher levels of hepatic triglyceride content and inflammation and is most 
common is persons of Hispanic/Latino background 11.
Kallwitz et al. Page 6






















Hispanic/Latino populations in different regions have a variable mixture of Native 
American, European and African Ancestry 23, potentially affecting the genetic risk for 
NAFLD. The risk allele also has been shown to confer susceptibility to increased hepatic fat 
content resulting from dietary intake 24. Carbohydrate consumption in children was 
associated with excess hepatic fat content only in the cohort that had the PNPLA3 high risk 
allele suggesting the importance of genetic predisposition and lifestyle choices in the 
development of NAFLD 24. As such, the prevalence of NAFLD in specific populations 
appears to result from a complex interaction of behavioral and genetic factors that are not 
fully understood. It is possible that further examination of dietary and lifestyle factors may 
factor into the presence and progression of NAFLD when evaluated in the context of groups 
with a greater genetic predisposition.
The current study has limitations similar to those of previous population-based studies that 
have estimated the prevalence of NAFLD. More specifically, aminotransferase thresholds 
were used as a surrogate biomarker for NAFLD, as the HCHS/SOL study did not include 
liver imaging or liver biopsies. The values of aminotransferases chosen as abnormal in the 
study were selected to be consistent with other large population-based studies 6. It has been 
noted that significant liver disease can occur in patients with NAFLD who have “normal” 
alanine aminotransferase levels 25. Additionally, there is incomplete consensus on what 
constitutes the upper limit of normal for aminotransferases with more stringent criteria being 
proposed 26. When more stringent cut off values for ALT of > 19 in women and > 30 in men 
were applied to this population, 43.0% of women and 40.4% of men had an elevated level. 
Other causes of elevated aminotransferases such as medication-induced liver injury, 
autoimmune hepatitis, and other metabolic or genetic liver diseases were not excluded in the 
present analysis. However, based on prevalence data for these disorders, the impact of 
inclusion of these diseases is likely minimal. The higher prevalence of suspected NAFLD in 
younger persons deserves further comment. Alanine aminotransferase activity has been 
shown to decrease with age 27, thus potentially underestimating the prevalence of NAFLD in 
older persons in this study. Finally self-reported data for alcohol consumption, diet, physical 
activity and acculturation are subject to reporting bias. The major strengths of this study are 
the large number of Hispanic/Latino individuals from diverse backgrounds and the 
systematic collection of data on components of the metabolic syndrome, behavioral factors, 
and acculturation.
Hispanics/Latinos are now the largest and fastest growing minority group in the United 
States. Thus, it is important to more fully understand disease processes which 
disproportionally affect Hispanic/Latino populations. NAFLD has a particularly high 
prevalence in Hispanic/Latino individuals compared to other ethnic groups and Hispanic/
Latinos are over-represented in cohorts with cirrhosis from NAFLD 28. Identification of 
Hispanic/Latino groups at the greatest risk for liver disease is important for identifying 
underlying NAFLD, implementing early interventions with lifestyle modification, and 
initiating appropriate evaluation for risk of cirrhosis and liver cancer. Data from the current 
study show that the risk of NAFLD is not equal in persons of Hispanic/Latino background. 
Genetic differences based on ancestral origins of Hispanic/Latino groups offer a plausible 
hypothesis that merits future study. Such studies could include measurement of PNPLA3 
Kallwitz et al. Page 7






















risk alleles in a diverse group of Hispanic persons and further examination of dietary and 
behavioral measures in the context of underlying genetic risk.
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Age-Standardized Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) based on 
elevated aminotransferase for All Participants, Men and Women and by Hispanic/Latino 
Background Group after excluding other etiologies (*p<0.05, ***p<0.001)
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Table 2
Univariate Results for the Association of Metabolic, Socio-demographic, and Behavioral Factors with 
Suspected Nonalcoholic Fatty Liver Disease (NAFLD)
Variable All Participants (N=12,133) Women (N=7,589) Men (N=4,544)
Age
18–30(reference group) 1 1 1
30–40 1.32(1.09,1.61)*** 1.32(0.96,1.83) 1.39(1.04,1.85)*
40–50 1.08(0.90,1.31)*** 1.32(1.01,1.73)* 0.97(0.74,1.27)
50–60 1.09(0.88,1.34)*** 1.70(1.24,2.34)** 0.75(0.56,1.00)*
60+ 0.68(0.54,0.86)*** 1.15(0.83,1.61) 0.43(0.30,0.61)***
Female 0.62(0.53,0.71)*** -- --
Hispanic/Latino origin group
Mexican(reference group) 1 1 1
Cuban 0.71(0.59,0.86)** 0.57(0.44,0.73)*** 0.75(0.58,0.98)*
Puerto Rican 0.65(0.52,0.82)** 0.79(0.57,1.09) 0.52(0.38,0.72)***
Dominican 0.62(0.48,0.81)** 0.54(0.38,0.76)** 0.76(0.52,1.09)
Central American 0.93(0.75,1.16) 0.97(0.74,1.29) 0.87(0.64,1.18)
South American 0.75(0.59,0.96)* 0.73(0.53,1.01) 0.76(0.54,1.09)
Metabolic syndrome (present/absent) 2.18(1.90,2.50)*** 2.54(2.11,3.05)*** 1.98(1.62,2.41)***
Waist circumference (elevated/normal) 1.64(1.43,1.88)*** 2.71(2.14,3.45)*** 1.95(1.62,2.36)***
Triglycerides (elevated/normal) 2.28(1.97,2.63)*** 2.31(1.90,2.80)*** 2.06(1.69,2.51)***
HDL(low/normal) 1.67(1.45,1.92)*** 2.02(1.67,2.44)*** 1.67(1.37,2.05)***
Blood pressure (elevated/normal) 1.47(1.22,1.77)*** 1.30(0.98,1.74) 1.44(1.11,1.86)**
Fasting glucose (elevated/normal) 1.73(1.47,2.04)*** 2.59(2.08,3.22)*** 1.15(0.90,1.47)
Acculturation (language preference) 0.97(0.92,1.03) 0.94(0.86,1.02) 0.97(0.89,1.05)
Physician visit 1.00(0.98,1.01) 1.01(0.99,1.02) 0.99(0.98,1.01)
Sleep disturbance 1.00(0.93,1.08) 1.06(0.96,1.17) 1.00(0.90,1.11)
Total carbohydrate 9.83(3.54,27.35)*** 0.34(0.04,3.15) 2.50(0.51,12.28)
Physical activity(quartile)
Quartile 1(reference group) 1 1 1
Quartile 2 1.02(0.85,1.24) 1.02(0.80,1.30) 1.02(0.76,1.37)
Quartile 3 0.88(0.73,1.06) 0.81(0.63,1.03) 0.84(0.62,1.12)
Quartile 4 1.07(0.89,1.29) 0.76(0.57,1.02) 0.98(0.75,1.28)
Education
<=12 years(reference group) 1 1 1
13–15 years 0.88(0.74,1.04) 0.74(0.58,0.93)* 1.03(0.82,1.30)
>=16 years 0.94(0.78,1.14) 0.85(0.65,1.11) 1.02(0.78,1.34)
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Variable All Participants (N=12,133) Women (N=7,589) Men (N=4,544)
Income
Less $10,000(reference group) 1 1 1
10,001–$20,000 1.06(0.85,1.31) 1.07(0.85,1.36) 0.96(0.66,1.41)
$20,001–$40,000 1.10(0.89,1.36) 0.98(0.77,1.26) 1.08(0.75,1.55)
$40,001–$75,000 1.10(0.85,1.44) 0.97(0.63,1.48) 1.03(0.69,1.54)







Data displayed in Odds ratios and 95% confidence intervals






















Kallwitz et al. Page 14
Table 3
Multivariable Association of Metabolic, Sociodemographic, and Behavioral Factors and Suspected 
Nonalcoholic Fatty Liver Disease (NAFLD)
Elevated aminotransferase levels All Participants Women Men
Age
18–30(reference group) 1 1 1
30–40 1.09(0.88,1.34) 1.09(0.77,1.54) 1.10(0.83,1.47)
40–50 0.77(0.62,0.95)* 0.96(0.70,1.33) 0.66(0.48,0.90)**
50–60 0.72(0.56,0.91)** 1.15(0.79,1.68) 0.45(0.32,0.62)***
60+ 0.43(0.33,0.56)*** 0.77(0.52,1.15) 0.25(0.17,0.37)***
Female 0.49(0.40,0.60)*** NA NA
Hispanic/Latino origin group
Mexican(reference group) 1 1 1
Cuban 0.69(0.57,0.85)*** 0.55(0.42,0.72)*** 0.83(0.62,1.10)
Puerto Rican 0.67(0.52,0.87)** 0.71(0.51,0.98)* 0.58(0.41,0.83)**
Dominican 0.71(0.54,0.93)* 0.59(0.41,0.85)** 0.84(0.57,1.25)
Central American 0.93(0.75,1.15) 0.99(0.76,1.30) 0.86(0.63,1.17)
South American 0.86(0.66,1.13) 0.86(0.60,1.22) 0.84(0.58,1.23)
Waist circumference (elevated/normal) 1.95(1.67,2.28)*** 2.13(1.65,2.75)*** 1.89(1.54,2.33)***
Triglycerides (elevated/normal) 1.76(1.50,2.07)*** 1.59(1.29,1.97)*** 1.82(1.44,2.29)***
HDL(low/normal) 1.33(1.16,1.54)*** 1.55(1.27,1.90)*** 1.23(0.99,1.53)
Blood pressure (elevated/normal) 1.30(1.06,1.61)* 1.11(0.80,1.56) 1.46(1.10,1.94)**
Fasting glucose (elevated/normal) 1.53(1.26,1.86)*** 1.96(1.53,2.50)*** 1.24(0.93,1.65)
Acculturation (language preference) 0.96(0.89,1.03) 0.99(0.90,1.09) 0.94(0.84,1.04)
Healthcare use 1.00(0.99,1.02) 1.00(0.99,1.02) 1.01(0.99,1.03)
Sleep disturbance 1.04(0.96,1.12) 1.04(0.95,1.15) 1.02(0.91,1.15)
Total Carbohydate 1.26(0.33,4.91) 0.68(0.08,6.06) 1.01(0.99,1.03)
Physical activity(quartile)
Quartile 1(reference group) 1 1 1
Quartile 2 1.04(0.86,1.27) 1.02(0.80,1.32) 1.05(0.77,1.43)
Quartile 3 0.85(0.70,1.03) 0.85(0.67,1.10) 0.82(0.60,1.13)
Quartile 4 0.91(0.74,1.10) 0.77(0.56,1.06) 0.90(0.68,1.21)
Education
<=12 years(reference group) 1 1 1
13–15 years 0.95(0.80,1.13) 0.86(0.68,1.09) 1.00(0.78,1.29)
>=16 years 1.08(0.89,1.31) 1.19(0.90,1.56) 1.09(0.82,1.46)
Income
Less $10,000(reference group) 1 1 1
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Elevated aminotransferase levels All Participants Women Men
10,001–$20,000 0.99(0.79,1.23) 1.13(0.88,1.46) 0.86(0.59,1.27)
$20,001–$40,000 1.01(0.81,1.26) 1.07(0.83,1.39) 0.95(0.66,1.38)
$40,001–$75,000 1.05(0.79,1.39) 1.15(0.76,1.74) 0.98(0.65,1.50)







Data displayed in Odds ratios and 95% confidence intervals
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